ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
TPX-0005 Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 1 week (NewB)
|
TPX-0005 Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 1 week - (New B)
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
entrectinib Sensitive: A1 - Approval
|
entrectinib Sensitive: A1 - Approval
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
lorlatinib Sensitive: A2 - Guideline
|
lorlatinib Sensitive: A2 - Guideline
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
ceritinib Sensitive: A2 - Guideline
|
ceritinib Sensitive: A2 - Guideline
|
ROS1 positive
|
Lung Cancer
|
ROS1 positive
|
Lung Cancer
|
lorlatinib Sensitive: C2 – Inclusion Criteria
|
lorlatinib Sensitive: C2 – Inclusion Criteria
|
ROS1 positive
|
Solid Tumor
|
ROS1 positive
|
Solid Tumor
|
TQ-B3101 Sensitive: C2 – Inclusion Criteria
|
TQ-B3101 Sensitive: C2 – Inclusion Criteria
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
brigatinib Sensitive: C2 – Inclusion Criteria
|
brigatinib Sensitive: C2 – Inclusion Criteria
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
TQ-B3101 Sensitive: C2 – Inclusion Criteria
|
TQ-B3101 Sensitive: C2 – Inclusion Criteria
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
TQ-B3139 Sensitive: C3 – Early Trials
|
TQ-B3139 Sensitive: C3 – Early Trials
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
AB-106 Sensitive: C3 – Early Trials
|
AB-106 Sensitive: C3 – Early Trials
|
ROS1 positive
|
Solid Tumor
|
ROS1 positive
|
Solid Tumor
|
TPX-0005 Sensitive: C3 – Early Trials
|
TPX-0005 Sensitive: C3 – Early Trials
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
ensartinib Sensitive: C3 – Early Trials
|
ensartinib Sensitive: C3 – Early Trials
|